BRIDGE 53

Despite its immense social relevance, the development of new therapies has not occurred to the desired extent in the past due to the high development risk, technical effort and correspondingly significant need for capital. There is also a lack of globally effective structures for transferring results from basic research to an industrial platform for the economically sound development of medicines for the treatment of infectious diseases (anti-infective drugs)..

Infection research has a long, historical tradition in Hamburg. As part of BRIDGE 53, Evotec SE is collaborating with Life Science Nord in working as an industrial partner with six academic institutions – the Bernhard Nocht Institute for Tropical Medicine, Deutsches Elektronen-Synchrotron, European Molecular Biology Laboratory, Heinrich Pette Institute, University of Hamburg, and the University Medical Center Hamburg-Eppendorf – in order to promote the validation of technological innovation potential in the research of new anti-infective drugs on a regional scale.

Informationen about BRIDGE 53 can be found here:
www.bridge53.org